Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C

NCT ID: NCT01740089

Last Updated: 2015-08-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-11-30
• Study Completion Date: 2013-12-31

Brief Summary

The purpose of the study is to demonstrate the noninferiority of Algeron 1.5 and 2.0 μg/kg/week in combination with ribavirin compared to PegIntron in combination with ribavirin in the treatment of chronic hepatitis C, and to determine therapeutic dose of Algeron.

Detailed Description

After 12 weeks of treatment, an assessment of treatment efficacy was performed, i.e. rates of rapid (after 4 weeks) and early (after 12 weeks) virologic responses according to serum HCV RNA level PCR data. In patients without virologic response after 12 weeks, AVT was discontinued, and they were withdrawn from the study. Patients with EVR were enrolled in a follow-up period. During the follow-up period, patients of the first and the second group will receive Algeron in the selected therapeutic dose in combination with ribavirin, patients of the third group - PegIntron in combination with ribavirin during 12 or 36 weeks (depending on a genotype of the virus), afterwards they will be followed up without therapy for 24 weeks.

Conditions

Hepatitis; Hepatitis C

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Algeron 1.5 μg/kg

Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg).

Group Type: EXPERIMENTAL

Algeron

Intervention Type: DRUG

1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously

Ribavirin

Intervention Type: DRUG

800-1400 mg/day orally

Algeron 2.0 μg/kg

Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg).

Group Type: EXPERIMENTAL

Algeron

Intervention Type: DRUG

1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously

Ribavirin

Intervention Type: DRUG

800-1400 mg/day orally

PegIntron

PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight \< 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight \> 105 kg).

Group Type: ACTIVE_COMPARATOR

PegIntron

Intervention Type: DRUG

1.5 μg/kg/week subcutaneously in combination with ribavirin

Ribavirin

Intervention Type: DRUG

800-1400 mg/day orally

Interventions

Algeron

1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously

Intervention Type: DRUG

PegIntron

1.5 μg/kg/week subcutaneously in combination with ribavirin

Intervention Type: DRUG

Ribavirin

800-1400 mg/day orally

Intervention Type: DRUG

Other Intervention Names

cepeginterferon alfa-2b; Peginterferon alfa-2b

Eligibility Criteria

Inclusion Criteria

1. Signed informed consent to participate in the study.

2. Hepatitis С virus infection (genotypes 1а, 1b, 2, 3, 4) confirmed by a positive quantitative PCR (HCV RNA > 50 IU/ml).

3. Males and females aged from 18 to 70 years inclusive.

4. Body mass index of 18 - 30 kg/m inclusive.

5. Increased ALT level (> 40, < 400 IU/L), documented at least twice within the last 6 months.

6. Preserved protein synthetic liver function (i.e. INR < 1.7, albumin > 35 g/l).

7. No signs of hepatic encephalopathy or abdominal fluid retention according to clinical and ultrasound examination.

8. Fertile patients and their partners agree to use barrier contraception throughout the study and 7 months after its completion.

Exclusion Criteria

1. Intolerance of IFN alpha formulations, ribavirin or any components of these drugs according to the past medical history.

2. Infection by hepatitis B virus or HIV.

3. Past history of HCV treatment with IFN alfa or pegylated IFN alfa formulations.

4. Administration of interferons and/or interferon inducing drugs for any indication within 1 month prior to the enrollment into the study.

5. Cholestatic hepatitis (conjugated bilirubin, alkaline phosphatase, ALT levels of more than 5 ULN).

6. Decompensated liver cirrhosis confirmed by laboratory findings (Child-Pugh class B, С) or ultrasound examination.

7. Any documented autoimmune diseases.

8. Hematologic (hemoglobin < 130 g/L for males and < 120 g/L for females; neutrophils < 1.5 х109/L; platelets < 90 х109/L) or biochemical abnormalities (creatinine level of more than 1.5 ULN, creatinine clearance less than 50 mL/min).

9. Documented diagnosis of hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia).

10. Heavy depression, any other mental disorders, which in the Investigator's opinion can be contraindications for antiviral treatment.

11. Epilepsy and/or other functional disorders of the central nervous system.

12. Abnormal thyroid function (TTH level beyond the normal values).

13. Malignant neoplasms.

14. Pregnancy, lactation period.

15. Severe comorbidities (for example, severe hypertension, severe coronary heart disease, decompensated diabetes mellitus), which in the Investigator's opinion can be contraindications for antiviral treatment.

16. Documented rare hereditary diseases, such as intolerance of lactose, sucrose, fructose, lactase deficiency or glucose-galactose malabsorption.

17. Current alcohol or drug abuse, which in the Investigator's opinion can be contraindications for antiviral treatment or restrict treatment compliance.

18. Simultaneous participation in other clinical trials or prior participation in this or another clinical trial within less than 30 days after its completion.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Biocad

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Olga Znoyko, professor

Role: PRINCIPAL_INVESTIGATOR

Moscow State University of Medicine and Dentistry

Marina Maevskaya, professor

Role: PRINCIPAL_INVESTIGATOR

The First Moscow State Sechenov Medical University

Svetlana Kizhlo

Role: PRINCIPAL_INVESTIGATOR

Health Department "Center for Prevention and Control of AIDS and Infectious Diseases"

Natalia Petrochenkova

Role: PRINCIPAL_INVESTIGATOR

Smolensk State Medical Academy

Semen Maximov

Role: PRINCIPAL_INVESTIGATOR

Moscow State University of Medicine and Dentistry

Firaja Nagimova

Role: PRINCIPAL_INVESTIGATOR

Kazan State Medical University

Vladimur Yakovlev

Role: PRINCIPAL_INVESTIGATOR

7. St. Petersburg State Institution of Health "Clinical Infectious Diseases Hospital named SP Botkin"

Locations

Moscow State University of Medicine and Dentistry

Moscow, , Russia

Countries

Russia

Other Identifiers

PEG-IFNа-2

Identifier Type: -

Identifier Source: org_study_id